Zobrazeno 1 - 10
of 45
pro vyhledávání: '"35"'
Autor:
Mark J. Ratain, Arlene A. Forastiere, Lei Ye, Robert F. Gagel, Ezra E.W. Cohen, Linda Janisch, Steven I. Sherman, Forlisa Nauling, David S. Hong, Chaan S. Ng, Razelle Kurzrock, Thomas Müller, Ranee Mehra, Douglas W. Ball, John W. Frye, David G. Pfister, Roger B. Cohen, Ravi Salgia
Publikováno v:
Journal of Clinical Oncology. 29:2660-2666
Purpose XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models. Early observations of clinical benefit
Autor:
Sylke Nagel, Aruna Raghavachar, Ludwig Fischer von Weikersthal, Monika Serke, Ernst-Wilhelm Schmidt, Christine Lautenschlaeger, Hans Schweisfurth, Wolfgang Schuette, Ina Dittrich, Klaus Hans, Thomas Blankenburg, Angelika Reißig
Publikováno v:
Journal of Clinical Oncology. 23:8389-8395
Purpose A phase III study to determine whether a weekly docetaxel schedule improves the therapeutic index compared with the classic 3-weekly schedule. Patients and Methods Patients with stage IIIB-IV non–small-cell lung cancer (NSCLC) were randomly
Autor:
Christopher Sweeney, Eric Winquist, Darren R. Feldman, Ugo De Giorgi, Daniel Y.C. Heng, Silke Gillessen, Michal Chovanec, Jourik A. Gietema, Robert Huddart, Costantine Albany, Fay H. Cafferty, Peter Grimison, Aaron R. Hansen, Carsten Bokemeyer, Karim Fizazi, Jörg Beyer, Christian D. Fankhauser, Nicolas Sauvé, Alexey Tryakin, Torgrim Tandstad, Olof Ståhl, Helene F. S. Negaard, Ronald de Wit, Anja Lorch, Andrea Necchi, David J. Vaughn, Angelika Terbuch, Axel Heidenreich, Cora N. Sternberg, Marcus Hentrich, Xavier Garcia-del-Muro, Gedske Daugaard, Laurence Collette, Jonathan Shamash
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
J Clin Oncol
Gillessen, Silke; Sauvé, Nicolas; Collette, Laurence; Daugaard, Gedske; de Wit, Ronald; Albany, Costantine; Tryakin, Alexey; Fizazi, Karim; Stahl, Olof; Gietema, Jourik A; De Giorgi, Ugo; Cafferty, Fay H; Hansen, Aaron R; Tandstad, Torgrim; Huddart, Robert A; Necchi, Andrea; Sweeney, Christopher J; Garcia-Del-Muro, Xavier; Heng, Daniel Y C; Lorch, Anja; ... (2021). Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(14), pp. 1563-1574. 10.1200/JCO.20.03296
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(14), 1563-+. AMER SOC CLINICAL ONCOLOGY
Universidad de Barcelona
J Clin Oncol
Gillessen, Silke; Sauvé, Nicolas; Collette, Laurence; Daugaard, Gedske; de Wit, Ronald; Albany, Costantine; Tryakin, Alexey; Fizazi, Karim; Stahl, Olof; Gietema, Jourik A; De Giorgi, Ugo; Cafferty, Fay H; Hansen, Aaron R; Tandstad, Torgrim; Huddart, Robert A; Necchi, Andrea; Sweeney, Christopher J; Garcia-Del-Muro, Xavier; Heng, Daniel Y C; Lorch, Anja; ... (2021). Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(14), pp. 1563-1574. 10.1200/JCO.20.03296
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(14), 1563-+. AMER SOC CLINICAL ONCOLOGY
PURPOSE The classification of the International Germ Cell Cancer Collaborative Group (IGCCCG) plays a pivotal role in the management of metastatic germ cell tumors but relies on data of patients treated between 1975 and 1990. MATERIALS AND METHODS Da
Publikováno v:
Journal of Clinical Oncology. 16:1844-1848
PURPOSE Both paclitaxel and carboplatin have single-agent activity against carcinoma of the urothelium. We evaluated the combination of paclitaxel and carboplatin in the treatment of advanced cancers of the urothelium. PATIENTS AND METHODS Patients w
Autor:
Matthew A. Williams, Robert B. Livingston, G. K. Ellis, C A Long, R White, C McGuirt, Julie R. Gralow, B B Adamkiewicz
Publikováno v:
Journal of Clinical Oncology. 15:1395-1400
PURPOSE We evaluated weekly single-agent intravenous (IV) vinorelbine as salvage therapy for metastatic breast cancer. After the first five patients, all received elective growth factor support with granulocyte colony-stimulating factor (G-CSF; filgr
Autor:
E I Smith, Bennett L. Leventhal, Vijay V. Joshi, Donald H. Mahoney, Robert P. Castleberry, R L Berkow, Alexander A. Green, Alan B. Cantor, George R. Buchanan, F A Hayes
Publikováno v:
Journal of Clinical Oncology. 12:1616-1620
PURPOSE Children less than 1 year of age with metastatic neuroblastoma NB are at high risk of death. The need to identify new and effective chemotherapy agents is clear. A study was conducted by the Pediatric Oncology Group (POG) to determine the eff
Autor:
T M Waits, Mary L. McMaster, F A Greco, John D. Hainsworth, Richard S. Stein, S. N. Wolff, David H. Johnson, John P. Greer
Publikováno v:
Journal of Clinical Oncology. 11:943-949
PURPOSE Despite substantial advances in the treatment of aggressive non-Hodgkin's lymphoma, therapeutic results with conventional regimens remain poor in some subsets of patients. In an attempt to improve the prognosis of such patients we used an 8-w
Autor:
Apurvasena Parikh, Colin D. Weekes, Monica Motwani, Daniel Morgensztern, Huibin Yue, Edward B. Reilly, John Nemunaitis, Todd M. Bauer, Ramesh K. Ramanathan, Daniel E. H. Afar, Rebecca S. Heist, Karen Kelly, Eric Angevin, John H. Strickler, Louie Naumovski
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 33
Strickler, JH; Weekes, CD; Nemunaitis, J; Ramanathan, RK; Heist, RS; Morgensztern, D; et al.(2018). First-in-Human Phase I, Dose-Escalation and-Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2018787697. doi: 10.1200/jco.2018.78.7697. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/8bt41691
Strickler, JH; Weekes, CD; Nemunaitis, J; Ramanathan, RK; Heist, RS; Morgensztern, D; et al.(2018). First-in-Human Phase I, Dose-Escalation and-Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2018787697. doi: 10.1200/jco.2018.78.7697. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/8bt41691
Purpose This first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly called ABBV-399, an antibody–drug conjugate of the anti–c-Met monoclonal antibody ABT-700 and monomethyl auristatin E. Materials and Methods For dose escalatio
Autor:
Yenting Ngai, Julian Singer, Mark Napier, Abhro Chaudhuri, Rachel Lillywhite, Michael Gandy, Robin M. Rudd, Fiona H Blackhall, Samreen Ahmed, David Ferry, Allan Hackshaw, Marianne Nicolson, Arrigo Capitanio, Gary Middleton, Natasha Iles, Siow Ming Lee, Mary Falzon, B. Crosse, James Spicer, Martin Forster, Sally-Ann Rolls, J. Hicks, Conrad R. Lewanski
Publikováno v:
Lee, S M, Falzon, M, Blackhall, F, Spicer, J, Nicolson, M, Chaudhuri, A, Middleton, G, Ahmed, S, Hicks, J, Crosse, B, Napier, M, Singer, J M, Ferry, D, Lewanski, C, Forster, M, Rolls, S-A, Capitanio, A, Rudd, R, Iles, N, Ngai, Y, Gandy, M, Lillywhite, R & Hackshaw, A 2017, ' Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer : ERCC1 Trial (ET) ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 35, no. 4, pp. 402-411 . https://doi.org/10.1200/JCO.2016.68.1841
Purpose Retrospective studies indicate that expression of excision repair cross complementing group 1 (ERCC1) protein is associated with platinum resistance and survival in non–small-cell lung cancer (NSCLC). We conducted the first randomized trial
Autor:
William C. Wood, Fengmin Zhao, Vicky Jones, Silvana Martino, Nancy E. Davidson, Vered Stearns, Molin Wang, Tom Saphner, George W. Sledge, Joseph A. Sparano, Edith A. Perez, Bryan P. Schneider, Antonio C. Wolff
Publikováno v:
Journal of Clinical Oncology. 30:3051-3057
Purpose Neuropathy is a common and potentially disabling complication of adjuvant taxane therapy. Recent studies have identified candidate single nucleotide polymorphisms associated with taxane-induced neuropathy. Therefore, we sought to determine wh